Table S1. SNPs of *CTNNBIP1* associated with platinum treatment response of EOC patients

SNP	position	A1	A2	MAF	Platinum treatment response				
					OR (95%CI)	P^*	FDR	FPRP	BFDP
rs1220405	9922245	A	G	0.305	0.61 (0.43-0.86)	**0.005**	1.00	0.124	0.446
rs935073	9923741	A	G	0.306	0.62 (0.44-0.88)	**0.007**	1.00	0.164	0.535
rs946275	9924957	C	A	0.305	0.62 (0.44-0.88)	**0.007**	1.00	0.164	0.535
rs1220418	9938819	C	T	0.305	0.62 (0.44-0.88)	**0.007**	1.00	0.164	0.535
rs935075	9942118	C	T	0.305	0.62 (0.44-0.88)	**0.007**	1.00	0.164	0.535
rs1220381	9948405	T	C	0.305	0.62 (0.44-0.88)	**0.007**	1.00	0.164	0.535
rs3120822	9955216	C	T	0.305	0.62 (0.44-0.88)	**0.007**	1.00	0.164	0.535
rs1220384	9956185	C	A	0.305	0.62 (0.44-0.88)	**0.007**	1.00	0.164	0.535
rs1220412	9926229	T	C	0.324	0.63 (0.45-0.88)	**0.007**	1.00	0.141	0.518
rs935072	9910357	A	T	0.298	0.63 (0.44-0.89)	**0.009**	1.00	0.174	0.568
rs2486084	9965425	G	A	0.323	0.63 (0.45-0.89)	**0.008**	1.00	0.174	0.568

Abbreviations: SNPs, single nucleotide polymorphisms; A1, Allele 1, the major allele; A2, Allele 2, the minor allele; EOC, epithelial ovarian carcinoma; OR, odds ratio; CI, confidence interval; FDR, false discovery rate; FPRP, false-positive report probability; BFDP, Bayesian false-discovery probability; MAF, minor allele frequency;

P^*, obtained in multivariate logistic regression analysis with variables including age, tumor grade, histological types, FIGO stage, residue, ascites and neoadjuvant chemotherapy.

*T*he results were in **bold,** if *P*<0.05

Table S2. Stepwise multivariate logistic regression analysis for the identification of significant

SNPs in EOC patients

Variables	Category	Frequency	OR (95%CI)	*P**
Age at diagnosis	≤54 / >54	228/199	1.08 (0.99-1.18)	0.057
FIGO Stage	I-II / III-IV	74/328	1.15 (1.03-1.29)	**0.015**
Residue	≤1cm / >1cm	276/55	1.31 (1.15-1.49)	**<0.001**
rs935072	AA / AT / TT	216/169/42	0.92 (0.87-0.98)	**0.014**

Abbreviations: SNPs, single nucleotide polymorphisms; EOC, epithelial ovarian carcinoma;

OR, odds ratio; CI, confidence interval; FIGO, international federation of gynecology and

obstetrics;

P^*, obtained in a stepwise multivariate logistic regression analysis, and variables included age,

tumor grade, histological types, FIGO stage, residue, ascites, neoadjuvant chemotherapy and

CTNNBIP1 rs935072;

The results were in bold, if *P*<0.05.

Supplementary Figure 1

Supplementary Figure 2

CTNNBIP1 rs935072

Supplementary Figure 3

A   *CTNNBIP1* rs935072
(1000 Genomes project)
P=0.937

B   *CTNNBIP1* rs935072
(CHB population of Hapmap3 database)
P=0.671